Activin A Receptor Type IB/ALK-4 antibody (N-Term)
The Rabbit Polyclonal anti-Activin A Receptor Type IB/ALK-4 antibody has been validated for WB and FACS. It is suitable to detect Activin A Receptor Type IB/ALK-4 in samples from Human, Mouse and Rat.
This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This Activin A Receptor Type IB (ACVR1B) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 39-68 amino acids from the N-terminal region of human Activin A Receptor Type IB (ACVR1B).
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date
6 months
Target
Activin A Receptor Type IB/ALK-4 (ACVR1B)
(Activin A Receptor, Type IB (ACVR1B))
Alternative Name
Activin A Receptor Type IB (ACVR1B)
Background
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with a cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. The gene for ACVR1B (activin A type IB receptor) is composed of 11 exons. Alternative splicing and alternative polyadenylation result in 3 fully described transcript variants. The mRNA expression of variants 1, 2, and 3 is confirmed, and a potential fourth variant contains an alternative exon 8 and lacks exons 9 through 11, but its mRNA expression has not been confirmed.